Table 1 Clinical characteristics and glutamate serum level among study groups
NMOSD (n = 30) | MS (n = 30) | |||||||
|---|---|---|---|---|---|---|---|---|
Patients with relapse (n = 15) | Patients in remission (n = 15) | Patients with relapse (n = 15) | Patients in remission (n = 15) | |||||
Range | Mean ± SD | Range | Mean ± SD | Range | Mean ± SD | Range | Mean ± SD | |
Age | 25–57 | 38.4 ± 7.68 | 19–53 | 38 ± 9.06 | 24–43 | 35 ± 6.4 | 26–45 | 33.2 ± 5.8 |
Age at onset (years) | 21–48 | 32. 73 ± 7. 72 | 19–49 | 33.2 ± 10.8 | 18–36 | 26 ± 7.06 | 18–37 | 26.53 ± 6.38 |
Duration of illness | 5 m–15 y | 5.17 ± 4.11 y | 5 m–16 y | 4.8 ± 4.6 y | 10 m–16 y | 7.03 ± 4.76 | 6 m–11 y | 5.36 ± 4.36 |
Last relapse to sampling duration | 4 m: 63 m | 29.4 ± 22.8 m | 1 day: 3 m | 1.02 ± 0.9 m | 3.47 m: 87 m | 16.6 ± 21.35 m | 1: 31 days | 13.3 ± 11.6 days |
Range | Median | Range | Median | Range | Median | Range | Median | |
|---|---|---|---|---|---|---|---|---|
Total number of relapses | 02-Jun | 3 | 01-Nov | 3 | 01-Oct | 3 | 01-Nov | 6 |
Number of relapses in the last year | 0–4 | 1 | 01-Mar | 2 | 0–4 | 1 | 1–5 | 3 |
Total EDSS | 1.5–7 | 4 | 02-Jul | 5 | 01-May | 2.5 | 1.5–5.5 | 2.5 |
Range | Mean ± SD | Range | Mean ± SD | Range | Mean ± SD | Range | Mean ± SD | |
|---|---|---|---|---|---|---|---|---|
Glutamate (μg/mL) | 8.2–33.6 | 16.82 ± 6.98 | 5.09–34.2 | 18.46 ± 8.76 | 5.3–17.5 | 10.84 ± 3.26 | 10.8–38.4 | 23.69 ± 8.64 |